If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
82.20    1.30 (1.61%)
Bid:
85.20
Ask:
73.00
Spread: -12.20 (-14.319%)
Market Cap: £134.76m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Q3 Trading Update

25 Oct 2019 07:00

RNS Number : 0931R
Synthomer PLC
25 October 2019
 

 

October 25th 2019

 

Synthomer plc

Q3 Trading Update

Continued challenges in European SBR market; Revised FY outlook

 

Synthomer plc ("Synthomer" or "the Group") today issues a trading update for the third quarter ("Q3") ended September 30th 2019.

 

Trading

 

The growing weakness in the global economy has created a more challenging backdrop for the Chemical industry. Depressed European industrial activity combined with increased political and economic uncertainties have resulted in an overall slower trading environment throughout Q3.

 

Performance Elastomers

 

In this environment, Nitrile Butadiene Latex (NBR) had another positive quarter with continued growth supported by the additional 90 ktes of capacity introduced during Q4 2018. NBR volumes increased further during Q3 with year-to-date unit margins remaining stable.

 

In SBR, the Group highlighted challenging conditions in Europe at its H1 results in August. Conditions have not improved during Q3 and the Group's Paper segment has also continued to remain particularly weak. Accordingly, management now expect SBR volumes to be approximately 10% behind 2018 and unit margins to also be similarly lower than last year. A review of network utilisation is currently underway and an update on asset re-purposing and cost base will be provided in conjunction with the Full Year results in March 2020.

 

Functional Solutions

 

Notwithstanding the impact of tough market conditions, overall performance was in line with the first nine months of 2018, with lower volumes offset by higher unit margins. The Group expects to see the benefits of additional capacity at Worms (Germany) and Roebuck (USA) continue to come through in line with the investment case.

 

Industrial Specialities

 

Industrial Specialities continued to trade in-line with management expectations. Volumes and margins were broadly flat with the first nine months of 2018.

 

Financial position

 

At 30 September 2019, the Group remained conservatively levered with net debt/EBITDA, excluding the net proceeds of the rights issue, of 1.4x (30 September 2018: 1.4x).

 

Proposed acquisition of Omnova Solutions Inc.

 

Following approval by both sets of shareholders and competition clearance in the US, the transaction remains subject only to regulatory approval from the European and Turkish competition authorities, and the Group continues to target completion in late 2019.

 

There has been no material change to the expected de-leveraging profile of the Enlarged Group as announced at the time of the transaction.

 

Management remain confident of delivering a swift integration and synergies during 2020.

 

2019 Outlook

 

Whilst Synthomer continues to benefit from its strong product portfolio, end market diversification and geographic presence, the slower trading environment is expected to continue through the remainder of the year and into 2020, particularly in Europe.

 

Whilst Functional Solutions and Industrial Specialities are now expected to be in-line with the prior year, with NBR ahead of 2018, results for the Full Year will be adversely impacted by the increased weakness in the European SBR business.

 

If the current weakness in macroeconomic conditions persist through Q4, excluding any impact from the potential acquisition of OMNOVA, the Board expects underlying profit before tax for FY 2019 to be approximately 10% below 2018 and accordingly current consensus expectations*.

 

- Ends -

 

* Teneo compiled Company consensus: FY 2019 underlying profit before tax - £135.3m

 

Enquiries:

 

Calum MacLean, Chief Executive Officer

Stephen Bennett, Chief Financial Officer

Tim Hughes, Head of Investor Relations

 

Tel: + 44 1279 436211

Charles Armitstead, Teneo

Tel: + 44 7703 330 269

 

The Company will hold a conference call for investors and analysts at 0800 BST today:

Dial in number: 08003589473 PIN: 25297905#

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTUSUWRKUARUAA
Date   Source Headline
6th Mar 20258:32 amRNSDirector Declaration
13th Feb 20257:00 amRNSHolding(s) in Company
28th Jan 202510:30 amRNSDirector/PDMR Shareholding
28th Jan 20257:00 amRNSWinter trading statement
2nd Jan 20259:00 amRNSDirectorate Change
31st Oct 20247:00 amRNSTrading statement - Autumn 2024
17th Oct 20244:01 pmRNSHolding(s) in Company
14th Oct 20241:51 pmRNSHolding(s) in Company
27th Sep 202412:46 pmRNSHolding(s) in Company
19th Sep 20241:01 pmRNSHolding(s) in Company
13th Aug 20247:00 amRNSInterim results
18th Jul 202412:53 pmRNSChair succession and other board changes
17th May 20248:20 amRNSPost Stabilisation Notice
9th May 20242:29 pmRNSResults of AGM
9th May 20247:00 amRNSTrading Statement - Spring 2024
1st May 20247:00 amRNSDivestment of Compounds completed
25th Apr 20244:30 pmRNSDirector/PDMR Shareholding
25th Apr 20244:20 pmRNSDirector/PDMR Shareholding
17th Apr 202410:43 amRNSTender offer results
15th Apr 20247:00 amRNSDivestment of Compounds
12th Apr 20247:00 amRNSPricing of senior notes
9th Apr 20243:47 pmRNSPre Stabilisation Notice
9th Apr 20248:09 amRNSNotice of tender offer
9th Apr 20248:09 amRNSProposed offering of senior notes
28th Mar 20242:38 pmRNSDirector/PDMR Shareholding
28th Mar 20242:38 pmRNSDirector/PDMR Shareholding
28th Mar 20242:10 pmRNSAnnual Financial Report and Notice of AGM
12th Mar 20247:00 amRNSFinal Results
30th Jan 20247:00 amRNSTrading Statement
17th Jan 20242:58 pmRNSExternal Appointment
15th Nov 20237:00 amRNSTrading statement - Autumn 2023
3rd Nov 20232:54 pmRNSDirector/PDMR Shareholding
23rd Oct 20231:58 pmRNSDirector/PDMR Shareholding
18th Oct 20237:00 amRNSDirector/PDMR Shareholding
17th Oct 20237:00 amRNSDirector/PDMR Shareholding
16th Oct 20233:13 pmRNSHolding(s) in Company - CORRECTION
16th Oct 202312:06 pmRNSHolding(s) in Company
16th Oct 202312:03 pmRNSHolding(s) in Company
16th Oct 202311:57 amRNSHolding(s) in Company
16th Oct 20237:00 amRNSTotal Voting Rights
16th Oct 20237:00 amRNSPDMR and PCA Notification
13th Oct 20234:18 pmRNSHolding(s) in Company
13th Oct 202310:48 amRNSHolding(s) in Company
13th Oct 20237:00 amRNSResult of rump placing
12th Oct 20234:36 pmRNSResult of Equity Issue
12th Oct 202310:09 amRNSHolding(s) in Company
11th Oct 20239:39 amRNSHolding(s) in Company
11th Oct 20237:00 amRNSPDMR PCA Notification
10th Oct 20233:04 pmRNSHolding(s) in Company
10th Oct 202310:26 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.